Evaluation of BTX Injections in Treatment of Bruxism

Launched by ALEXANDRIA UNIVERSITY · Aug 4, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the use of injections of a medication called botulinum toxin type A (Xeomin®) to help people who suffer from bruxism, which is the involuntary grinding or clenching of teeth. The goal is to see if this treatment can reduce pain and muscle activity in the jaw for individuals who have not found relief from traditional treatments like pain relievers, physical therapy, or dental devices. The study will involve 12 participants between the ages of 20 and 60 who experience pain in their jaw muscles due to bruxism and have never had botulinum toxin injections before.

If you qualify for the trial, you will receive injections in specific jaw muscles and then be monitored for any changes in pain levels and muscle activity at 1 and 3 months after the treatment. It’s important to know that this trial is not open for recruitment yet, and certain individuals, such as pregnant or breastfeeding women and those with specific neurological conditions, will not be eligible to participate. This study aims to find a new way to help those who struggle with bruxism and may provide valuable information for future treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patient between 20 and 60 years of age.
• • 2. Pain related to the masseter muscles and TMJ area due to bruxism.
• • 3. Patient who has never received botulinum toxins.
• • 4. Patient who did not respond to the conventional treatments (analgesic, physiotherapy, relaxation technique and maxillary retainer).
• Exclusion Criteria:
• • 1. Pregnant or breastfeeding women.
• • 2. Neuromuscular diseases, including neurogenic impairment of the face and patients with underlying neurological disorders.
• • 3. Patients with epilepsy or a previous seizure episode.
• • 4. Injection site infection (masseter or temporalis).
• • 5. Hypersensitivity or allergy to botulinum toxin or any of its excipients.